• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Myopia - Pipeline Review, H2 2012 Product Image

Myopia - Pipeline Review, H2 2012

  • Published: October 2012
  • 40 pages
  • Global Markets Direct

Myopia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Myopia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Myopia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myopia. Myopia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Myopia.
- A review of the Myopia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Myopia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Myopia 7
Myopia Therapeutics under Development by Companies 9
Myopia Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Myopia Therapeutics – Products under Development by Companies 13
Myopia Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Myopia Therapeutics Development 15
F. Hoffmann-La Roche Ltd. 15
Regeneron Pharmaceuticals, Inc. 16
Myopia – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
ranibizumab - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
aflibercept - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
bevacizumab - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
atropine sulfate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
bevacizumab - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Myopia Therapeutics – Drug Profile Updates 30
Myopia Therapeutics - Dormant Products 37
Myopia – Product Development Milestones 38
Featured News & Press Releases 38
Jan 03, 2012: Regeneron Announces Settlement Of Patent Litigation With Genentech For US Ophthalmic Sales Of EYLEA Injection 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products Under Development for Myopia, H2 2012 7
Products under Development for Myopia – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
F. Hoffmann-La Roche Ltd., H2 2012 15
Regeneron Pharmaceuticals, Inc., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Myopia Therapeutics – Drug Profile Updates 30
Myopia Therapeutics – Dormant Products 37

List of Figures
Number of Products under Development for Myopia, H2 2012 7
Products under Development for Myopia – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos